| [1] |
Liu ZH. Nephrology in china [J]. Nat Rev Nephrol, 2013, 9(9): 523-528.
|
| [2] |
Tanaka T, Nangaku M. Angiogenesis and hypoxia in the kidney [J]. Nat Rev Nephrol, 2013, 9(4): 211-222.
|
| [3] |
Satoh M, Kidokoro K, Ozeki M, et al. Angiostatin production increases in response to decreased nitric oxide in aging rat kidney [J]. Lab Invest, 2013, 93(3): 334-343.
|
| [4] |
O′Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [J]. Cell, 1994, 79(2): 315-328.
|
| [5] |
Lay AJ, Jiang XM, Daly E, et al. Plasmin reduction by phosphoglycerate kinase is a thiol-independent process [J]. J Biol Chem, 2002, 277(11): 9062-9068.
|
| [6] |
Butera D, Wind T, Lay AJ, et al. Characterization of a reduced form of plasma plasminogen as the precursor for angiostatin formation [J]. J Biol Chem, 2014, 289(5): 2992-3000.
|
| [7] |
Molema G, van Veen-Hof I, van Loenen-Weemaes AM, et al. Pharmacokinetics and whole body distribution of elastase derived angiostatin (K1-3) in rats [J]. Int J Cancer, 2001, 91(1): 1-7.
|
| [8] |
Migita T, Oda Y, Naito S, et al. The accumulation of angiostatin-like fragments in human prostate carcinoma [J]. Clin Cancer Res, 2001, 7(9): 2750-2756.
|
| [9] |
van Tilborg AA, Sweep FC, Geurts-Moespot AJ, et al. Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids [J]. Int J Oncol, 2014, 44(4): 1394-1400.
|
| [10] |
Dodd T, Wiggins L, Hutcheson R, et al. Impaired coronary collateral growth in the metabolic syndrome is in part mediated by matrix metalloproteinase 12-dependent production of endostatin and angiostatin [J]. Arterioscler Thromb Vasc Biol, 2013, 33(6): 1339-1349.
|
| [11] |
Oh ET, Park MT, Song MJ, et al. Radiation-induced angiogenic signaling pathway in endothelial cells obtained from normal and cancer tissue of human breast [J]. Oncogene, 2014, 33(10): 1229-1238.
|
| [12] |
Fliedner SM, Yang C, Thompson E, et al. Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells [J]. Am J Cancer Res, 2015, 5(4): 1558-1570.
|
| [13] |
Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells [J]. J Biol Chem, 2001, 276(43): 39562-39568.
|
| [14] |
Takada Y. Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis) [J]. J Biomed Biotechnol, 2012, 2012: 136302.
|
| [15] |
Moleirinho S, Guerrant W, Kissil JL. The Angiomotins--from discovery to function [J]. FEBS Lett, 2014, 588(16): 2693-2703.
|
| [16] |
Sheikh AQ, Taghian T, Hemingway B, et al. Regulation of endothelial MAPK/ERK signalling and capillary morphogenesis by low-amplitude electric field [J]. J R Soc Interface, 2013, 10(78): 20120548.
|
| [17] |
Keskin D, Keskin G, Inal A, et al. Serum angiostatin levels in patients with Behcet′s disease: does angiogenesis play a role in the pathogenesis of Behcet's disease? [J]. Acta Clin Belg, 2014, 69(4): 246-250.
|
| [18] |
Gok M, Erdem H, Gogus F, et al. Relationship of ultrasonographic findings with synovial angiogenesis modulators in different forms of knee arthritides [J]. Rheumatol Int, 2013, 33(4): 879-885.
|
| [19] |
Benelli R, Morini M, Carrozzino F, et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation [J]. FASEB J, 2002, 16(2): 267-269.
|
| [20] |
Perri SR, Annabi B, Galipeau J. Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton [J]. FASEB J, 2007, 21(14): 3928-3936.
|
| [21] |
MacMillan CJ, Doucette CD, Warford J, et al. Murine experimental autoimmune encephalomyelitis is diminished by treatment with the angiogenesis inhibitors B20-4.1.1 and angiostatin (K1-3) [J]. PLoS One, 2014, 9(2): e89770.
|
| [22] |
Jen KY, Haragsim L, Laszik ZG. Kidney microvasculature in health and disease [J]. Contrib Nephrol, 2011, 169: 51-72.
|
| [23] |
Matsumoto M, Tanaka T, Yamamoto T, et al. Hypoperfusion of peritubular capillaries induces chronic hypoxia before progression of tubulointerstitial injury in a progressive model of rat glomerulonephritis [J]. J Am Soc Nephrol, 2004, 15(6): 1574-1581.
|
| [24] |
Futrakul N, Yenrudi S, Sensirivatana R, et al. Peritubular capillary flow determines tubulointerstitial disease in idiopathic nephrotic syndrome [J]. Ren Fail, 2000, 22(3): 329-335.
|
| [25] |
Futrakul N, Kulaputana O, Futrakul P, et al. Enhanced peritubular capillary flow and renal function can be accomplished in normoalbuminuric type 2 diabetic nephropathy [J]. Ren Fail, 2011, 33(3): 312-315.
|
| [26] |
Wu T, Du Y, Han J, et al. Urinary angiostatin--a novel putative marker of renal pathology chronicity in lupus nephritis [J]. Mol Cell Proteomics, 2013, 12(5): 1170-1179.
|
| [27] |
Basile DP, Fredrich K, Weihrauch D, et al. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure [J]. Am J Physiol Renal Physiol, 2004, 286(5): F893-F902.
|
| [28] |
Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis [J]. Am J Kidney Dis, 2007, 49(2): 186-193.
|
| [29] |
Zhang K, Meng X, Li D, et al. Angiotensin(1-7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade [J]. Kidney Int, 2015, 87(2): 359-369.
|
| [30] |
Zhang SX, Wang JJ, Lu K, et al. Therapeutic potential of angiostatin in diabetic nephropathy [J]. J Am Soc Nephrol, 2006, 17(2): 475-486.
|
| [31] |
Alicic RZ, Tuttle KR. Novel therapies for diabetic kidney disease [J]. Adv Chronic Kidney Dis, 2014, 21(2): 121-133.
|